Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | MMP8 | P22894 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471176 | 1.00 | CFTR (0.40) | CFTRGRM2TRPV1RORCGNRHR | |
| SCHEMBL23958691 | 0.92 | CFTR (0.38) | CFTRGRM2TRPV1RORCGNRHR | |
| SCHEMBL25686644 | 0.91 | CFTR (0.39) | CFTRGRM2TRPV1RORCGNRHR | |
| SCHEMBL23958697 | 0.88 | CFTR (0.44) | CFTRGRM2RORCLATS1FPR2 | |
| SCHEMBL23958956 | 0.87 | CFTR (0.41) | CFTRGRM2RORCMMP8MMP3 | |
| SCHEMBL25686633 | 0.85 | CFTR (0.38) | CFTRTRPV1PTGS2FPR2SCN9A | |
| SCHEMBL25686632 | 0.85 | CFTR (0.38) | CFTRTRPV1PTGS2FPR2SCN9A | |
| SCHEMBL25686835 | 0.84 | CFTR (0.36) | CFTRGRM2TRPV1RORCLATS1 | |
| SCHEMBL25686536 | 0.83 | CFTR (0.42) | CFTRGRM2TRPV1RORCGNRHR | |
| SCHEMBL23958952 | 0.81 | CFTR (0.35) | CFTRGRM2TRPV1LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885GRM2 3975/4885TRPV1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.